Is the toxicity of adjuvant aromatase inhibitor therapy underestimated? Complementary information from patient-reported outcomes (PROs)
Authors:
- Anne OberguggenbergerAOAnne Oberguggenberger
- Michael HubalekMHMichael Hubalek
- Monika SztankayMSMonika Sztankay
- Verena MeranerVMVerena Meraner
- Beate BeerBBBeate Beer
- Herbert OberacherHerbert Oberacher
- Johannes GiesingerJGJohannes Giesinger
- Georg KemmlerGKGeorg Kemmler
- Daniel EgleDEDaniel Egle
- Eva-Maria GamperEGEva-Maria Gamper
- Barbara Sperner-UnterwegerBSBarbara Sperner-Unterweger
- Bernhard HolznerBHBernhard Holzner
- 11 February 2011
- journal article
- research article
- Published by Springer Nature in Breast Cancer Research and Treatment
- Vol. 128 (2) , 553-561
Abstract
Adjuvant endocrine treatment-related adverse effects have a strong impact on patients’ quality of life and thereby limit therapy’s risk benefit ratio resulting in morbidity and treatment discontinuation. Still, many AI adverse effects remain untreated given that they are unrecognized by conservative methods (e.g., proxy ratings). The ability of complementary patient-reported outcomes (PROs) to provide a more comprehensive assessment of side-effects is to be explored. A cross-sectional study sample of 280 postmenopausal, early stage breast cancer patients was subjected to a comprehensive PRO assessment (FACT-B/+ES) at their after-care appointment. Prevalence and severity of patient-reported physical side-effects and psychosocial burden related to adjuvant AI therapy were compared with prevalences derived from pivotal phase IV trials (ATAC 2005, BIG1-98 2005). Across all symptom categories, highest prevalence rates were found for joint pain (59.6%), hot flushes (52%), lost interest in sexual intercourse (51.4%), and lack of energy (40.3%). Overall, PROs resulted in significantly higher prevalence rates as compared to physician ratings for all symptoms published in pivotal clinical trials except vaginal bleeding and nausea. The treatment duration exerted no significant impact on symptom frequency (P > 0.05). Established prevalence rates of endocrine treatment-related toxicity seem to be underestimated. The incorporation of PRO data should be mandatory or at least highly recommended in clinical treatment planning to arrive at a more accurate assessment of a patient’s actual symptom burden enabling improved individualized management of side-effects and mediating the preservation of treatment adherence.Keywords
This publication has 34 references indexed in Scilit:
- Generalizing Evidence From Randomized Clinical Trials to Target Populations: The ACTG 320 TrialAmerican Journal of Epidemiology, 2010
- The Missing Voice of Patients in Drug-Safety ReportingNew England Journal of Medicine, 2010
- Towards the Implementation of Quality of Life Monitoring in Daily Clinical Routine: Methodological Issues and Clinical ImplicationBreast Care, 2009
- Generalizing from clinical trial data: A case study. The risk of suicidality among pediatric antidepressant usersStatistics in Medicine, 2008
- Recognition and management of treatment-related side effects for breast cancer patients receiving adjuvant endocrine therapyBreast Cancer Research and Treatment, 2007
- Quality of Life of Postmenopausal Women in the ATAC (“Arimidex”, Tamoxifen, Alone or in Combination) Trial after Completion of 5 years' Adjuvant Treatment for Early Breast CancerBreast Cancer Research and Treatment, 2006
- Patient‐reported outcomes and health‐related quality of life in effectiveness studies: pros and consDrug Development Research, 2006
- Adherence to MedicationNew England Journal of Medicine, 2005
- A Randomized Trial of Exemestane after Two to Three Years of Tamoxifen Therapy in Postmenopausal Women with Primary Breast CancerNew England Journal of Medicine, 2004
- Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC randomised trialThe Lancet, 2002